• LAST PRICE
    16.1600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    14.0000/ 1
  • Ask / Lots
    18.1000/ 2
  • Open / Previous Close
    --- / 16.1600
  • Day Range
    ---
  • 52 Week Range
    Low 3.8100
    High 22.5000
  • Volume
    8
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 17.23
TimeVolumeIGMS
09:32 ET2829317.3
09:34 ET80016.9181
09:36 ET445216.75
09:38 ET70916.3635
09:41 ET21816.6
09:43 ET1210016.64
09:45 ET80816.64
09:50 ET10016.64
09:54 ET70016.755
09:57 ET164416.66
09:59 ET721116.72
10:01 ET70016.51
10:03 ET20016.3
10:06 ET416316
10:08 ET1012915.985
10:10 ET388116.02
10:12 ET32316.025
10:14 ET20016.01
10:15 ET144116.24
10:17 ET10016.28
10:19 ET10016.37
10:21 ET54016.37
10:24 ET20016.37
10:26 ET402916.38
10:28 ET60016.29
10:30 ET498316.42
10:32 ET87016.3
10:33 ET10016.21
10:35 ET20016.32
10:37 ET70016.22
10:39 ET90016.21
10:42 ET144416.15
10:44 ET20016.18
10:46 ET50016.0349
10:51 ET3485316.12
10:55 ET60016.12
10:57 ET110016.125
11:00 ET115116.165
11:02 ET68316.02
11:06 ET190016.18
11:11 ET60016.185
11:13 ET20016.185
11:15 ET10016.185
11:18 ET160016.0704
11:20 ET10016.19
11:22 ET20016.19
11:24 ET20016.19
11:31 ET10016.09
11:33 ET90016.215
11:36 ET10016.12
11:38 ET20016.22
11:42 ET20016.1695
11:47 ET10016.23
11:54 ET32116.225
11:58 ET60016.33
12:00 ET311116.325
12:02 ET10016.33
12:03 ET184216.37
12:05 ET80016.3375
12:07 ET40016.32
12:09 ET10016.32
12:20 ET297916.135
12:21 ET40016.105
12:23 ET410015.92
12:25 ET25015.8401
12:30 ET177116.05
12:34 ET22115.9636
12:36 ET143216.07
12:38 ET21716.07
12:39 ET10016.07
12:41 ET130016.16
12:43 ET123616.16
12:50 ET30016.03
12:52 ET10016.1
12:54 ET10016.1
12:56 ET40016
12:57 ET20015.91
12:59 ET10015.9
01:01 ET128416
01:06 ET20015.8001
01:10 ET30015.98
01:17 ET40816.15
01:19 ET10516.0301
01:24 ET38216.11
01:30 ET20016.115
01:32 ET10016.11
01:46 ET130016.2
01:57 ET30016.315
02:00 ET22516.315
02:06 ET10016.35
02:24 ET28416.19
02:29 ET10016.21
02:31 ET10016.12
02:33 ET32216.21
02:36 ET20016.21
02:42 ET62916.2245
02:45 ET19916.265
02:47 ET50016.23
02:58 ET10016.245
03:02 ET30016.23
03:03 ET30016.15
03:05 ET10016.2
03:07 ET30016.205
03:09 ET10016.18
03:14 ET10016.16
03:16 ET10016.21
03:20 ET64416.04
03:21 ET22016.08
03:25 ET130016.105
03:27 ET150016.22
03:30 ET60716.23
03:32 ET20016.225
03:34 ET951916.39
03:36 ET291616.5521
03:38 ET160016.63
03:39 ET10016.69
03:41 ET813416.5956
03:43 ET50016.475
03:45 ET70016.51
03:48 ET90016.415
03:50 ET30016.375
03:52 ET502216.185
03:54 ET1458116.05
03:56 ET2920616.04
03:57 ET3640916.45
03:59 ET19812816.16
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIGMS
IGM Biosciences Inc
958.6M
-4.4x
---
United StatesSANA
Sana Biotechnology Inc
945.5M
-3.7x
---
United StatesNUVB
Nuvation Bio Inc
937.4M
-1.3x
---
United StatesAUTL
Autolus Therapeutics PLC
992.5M
-3.2x
---
United StatesCATX
Perspective Therapeutics Inc
892.1M
-9.5x
---
United StatesORKA
Oruka Therapeutics Inc
875.0M
-4.2x
---
As of 2024-09-23

Company Information

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Contact Information

Headquarters
325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
Phone
650-965-7873
Fax
302-655-5049

Executives

Chief Executive Officer, Director
Fred Schwarzer
Chief Financial Officer
Misbah Tahir
Chief Scientific Officer
Bruce Keyt
Chief Business Officer
Lisa Decker
Head - Research and Autoimmunity
Mary Harler

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$958.6M
Revenue (TTM)
$2.9M
Shares Outstanding
59.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.17
EPS
$-3.67
Book Value
$3.46
P/E Ratio
-4.4x
Price/Sales (TTM)
329.3
Price/Cash Flow (TTM)
---
Operating Margin
-8,144.69%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.